ZP
CSTL icon

Zimmer Partners’s Castle Biosciences CSTL Stock Holding History

Zimmer Partners’s Portfolio CSTL Stock Details CSTL Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2020
Q1 		– Sell
-51,000
Closed -$1.75M – 82
2019
Q4 		$1.75M Hold
51,000
– – 0.02% 70
2019
Q3 		$923K Buy
+51,000
New +$1.13M 0.01% 93

Other funds holding CSTL

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
NAM
Nexpoint Asset Management Dallas, Texas $1.49B AUM 61.08% 1-Year Est. Return
RI
RTW Investments New York $10B AUM 135.35% 1-Year Est. Return
WA
Wasatch Advisors Salt Lake City, Utah $15.3B AUM 25.06% 1-Year Est. Return
DCM
Driehaus Capital Management Chicago, Illinois $13.6B AUM 173.98% 1-Year Est. Return
Goldman Sachs
Goldman Sachs New York $871B AUM 31.28% 1-Year Est. Return
Wells Fargo
Wells Fargo San Francisco, California $530B AUM 22.01% 1-Year Est. Return
TFS
TrustCore Financial Services Brentwood, Tennessee $1.14B AUM 13.32% 1-Year Est. Return
AIM
ARK Investment Management St. Petersburg, Florida $12.9B AUM 64.92% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Zimmer Partners's CSTL Position: Q1 2020 in Review

Zimmer Partners sold out of Castle Biosciences (CSTL) in Q1 2020, closing a stake of 51,000 shares — an estimated $1.75M sold.

Zimmer Partners first reported a position in CSTL in Q3 2019 and held it in 2 quarters. The position peaked at $1.75M in Q4 2019. 89 funds tracked by Wall St. Rank hold CSTL as of Q1 2020.

  • Zimmer Partners reported no remaining Castle Biosciences position as of Q1 2020 after selling out during the quarter.
  • Zimmer Partners sold 51,000 Castle Biosciences shares in Q1 2020, an estimated $1.75M.
  • Zimmer Partners first reported a position in Castle Biosciences in Q3 2019 and held it in 2 quarters.
  • Zimmer Partners's Castle Biosciences position peaked at $1.75M in Q4 2019.
  • 89 funds tracked by Wall St. Rank held Castle Biosciences as of Q1 2020.

Based on Zimmer Partners's 13F filing for Q1 2020, filed 15 May 2020.